Dashboard
Manage Tickers

NUVLNuvalent, Inc.

Nasdaq nuvalent.com


$ 80.39 $ 1.35 (1.71 %)    

Monday, 15-Jul-2024 12:17:37 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 496.98 $ 0.25 (0.05 %)
DIA $ 403.01 $ 2.69 (0.67 %)
SPY $ 562.49 $ 0.31 (0.06 %)
TLT $ 93.10 $ 0.14 (0.15 %)
GLD $ 224.93 $ 1.51 (0.68 %)
$ 78.65
$ 79.04
$ 80.20 x 100
$ 0.00 x 0
$ 78.86 - $ 80.61
$ 39.86 - $ 89.39
257,560
na
5.05B
$ 1.59
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-09-2024 03-31-2024 10-Q
2 02-27-2024 12-31-2023 10-K
3 11-14-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-10-2022 09-30-2022 10-Q
8 08-10-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-29-2022 12-31-2021 10-K
11 11-10-2021 09-30-2021 10-Q
12 09-08-2021 06-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stifel-maintains-buy-on-nuvalent-raises-price-target-to-115
Stifel Maintains Buy on Nuvalent, Raises P...
07/10/2024 13:24:06

Stifel analyst Bradley Canino maintains Nuvalent (NASDAQ:NUVL) with a Buy and raises the price target from $103 to $115.

novavax-and-agios-pharmaceuticals-were-among-the-10-biggest-mid-cap-gainers-last-week-june-1-june-7-are-these-in-your-portfolio
Novavax And Agios Pharmaceuticals Were Amo...
06/09/2024 18:29:27

Mid-cap stocks saw significant gains last week, with top performers like AGIO, VRNT, and NVAX, causing analysts to raise their ...

wedbush-reiterates-outperform-on-nuvalent-maintains-99-price-target
Wedbush Reiterates Outperform on Nuvalent,...
05/17/2024 13:22:52

Wedbush analyst David Nierengarten reiterates Nuvalent (NASDAQ:NUVL) with a Outperform and maintains $99 price target.

nuvalents-nvl-655-receives-fda-breakthrough-therapy-designation
Nuvalent's NVL-655 Receives FDA Breakthrou...
05/16/2024 20:02:39

nuvalent-q1-2024-gaap-eps-069-misses-068-estimate
Nuvalent Q1 2024 GAAP EPS $(0.69) Misses $...
05/09/2024 10:36:31

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.69) per share which missed the analyst consensus estimate of $(0.68) by...

jefferies-initiates-coverage-on-nuvalent-with-buy-rating-announces-price-target-of-97
Jefferies Initiates Coverage On Nuvalent w...
04/17/2024 11:57:07

Jefferies analyst Roger Song initiates coverage on Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $97.

nuvalent-presents-new-preclinical-data-for-her2-selective-inhibitor-nvl-330-and-ros1-selective-inhibitor-zidesamtinib-at-aacr-annual-meeting-2024
Nuvalent Presents New Preclinical Data For...
04/08/2024 20:36:03

Preclinical data continue to support NVL-330's broad activity against HER2 oncogenic alterations, selectivity over wild-typ...

leerink-partners-upgrades-nuvalent-to-outperform-raises-price-target-to-110
Leerink Partners Upgrades Nuvalent to Outp...
04/01/2024 14:57:43

Leerink Partners analyst Andrew Berens upgrades Nuvalent (NASDAQ:NUVL) from Market Perform to Outperform and raises the pric...

jp-morgan-maintains-overweight-on-nuvalent-raises-price-target-to-98
JP Morgan Maintains Overweight on Nuvalent...
03/06/2024 15:58:40

JP Morgan analyst Anupam Rama maintains Nuvalent (NASDAQ:NUVL) with a Overweight and raises the price target from $68 to $98.

guggenheim-assumes-nuvalent-at-buy-announces-price-target-of-99
Guggenheim Assumes Nuvalent at Buy, Announ...
02/28/2024 19:44:49

Guggenheim analyst Kelsey Goodwin assumes Nuvalent (NASDAQ:NUVL) with a Buy rating and announces Price Target of $99.

bmo-capital-maintains-outperform-on-nuvalent-raises-price-target-to-102
BMO Capital Maintains Outperform on Nuvale...
02/28/2024 14:19:06

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $93 to ...

recap-nuvalent-q4-earnings
Recap: Nuvalent Q4 Earnings
02/27/2024 13:25:06

nuvalent-q4-eps-062-down-from-049-yoy-cash-balance-of-7199m
Nuvalent Q4 EPS $(0.62) Down From $(0.49) ...
02/27/2024 11:42:10

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.62) per share. This is a 26.53 percent decrease over losses of $(0.49) ...

nuvalent-secures-fda-breakthrough-therapy-designation-for-nvl-520
Nuvalent Secures FDA Breakthrough Therapy ...
02/27/2024 11:17:05

The BTD for NVL-520 is based on the preliminary safety and activity of NVL-520 in heavily pretreated patients with advanced ROS...

baird-initiates-coverage-on-nuvalent-with-outperform-rating-announces-price-target-of-105
Baird Initiates Coverage On Nuvalent with ...
02/23/2024 10:50:00

Baird analyst Colleen Kusy initiates coverage on Nuvalent (NASDAQ:NUVL) with a Outperform rating and announces Price Target ...

nuvalent-has-initiated-phase-2-portion-of-alkove-1-phase-12-trial-of-nvl-655-for-alk-positive-non-small-cell-lung-cancer-and-other-solid-tumors-following-alignment-with-fda-on-recommended-phase-2-dose-of-150-mg-once-daily
Nuvalent Has Initiated Phase 2 Portion Of ...
02/12/2024 11:32:40

nuvalent-announced-its-ontarget-2026-operating-plan-to-guide-efforts-towards-having-its-first-potential-approved-product-in-2026-with-operating-runway-anticipated-into-2027
Nuvalent Announced Its "OnTarget 2026" Ope...
01/08/2024 11:35:07

recap-nuvalent-q3-earnings
Recap: Nuvalent Q3 Earnings
11/14/2023 14:30:13

nuvalent-q3-eps-059-misses-058-estimate-net-proceeds-of-282m-from-public-offering-along-with-cash-cash-equivalents-and-marketable-securities-of-4133m-is-expected-to-extend-operating-runway-into-2027
Nuvalent Q3 EPS $(0.59) Misses $(0.58) Est...
11/14/2023 11:38:03

Nuvalent (NASDAQ:NUVL) reported quarterly losses of $(0.59) per share which missed the analyst consensus estimate of $(0.58) by...

bmo-capital-maintains-outperform-on-nuvalent-raises-price-target-to-79
BMO Capital Maintains Outperform on Nuvale...
10/19/2023 15:49:09

BMO Capital analyst Etzer Darout maintains Nuvalent (NASDAQ:NUVL) with a Outperform and raises the price target from $73 to ...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)
07/23/2024 Fastly, Inc. (FSLY)
07/29/2024 Enphase Energy, Inc. (ENPH)
07/30/2024 Rivian Automotive, Inc. (RIVN)
07/30/2024 Hertz Global Holdings, Inc. (HTZ)
08/02/2024 Humana Inc. (HUM)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)